Skip to main content
Premium Trial:

Request an Annual Quote

Ingenuity Signs $6M CRADA with FDA to Develop Biomarker, PGx Informatics

NEW YORK (GenomeWeb News) - Ingenuity Systems has entered into a three-year, $6 million Cooperative Research and Development Agreement with the US Food and Drug Administration that will expand the company’s content and software used in biomarker, Pharmacogenomic, and toxicogenomic research, the company said today.
 
Ingenuity said the partnership is aimed at supporting the FDA’s drug toxicity and side-effects research programs.
 
Ingenuity, a member of the Biomarkers Consortium, markets IPABiomarker, a module of its Ingenuity Pathways Analysis software that is designed to help researchers explore, analyze and interpret biomarker-related scientific literature and data.
 
The FDA has already integrated IPA with its in-house ArrayTrack bioinformatics system under an agreement penned in 2005.
 

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more